Literature DB >> 31487003

Downregulation of 14-3-3 Proteins in Alzheimer's Disease.

Qiang Gu1, Elvis Cuevas2, James Raymick2, Jyotshna Kanungo2, Sumit Sarkar2.   

Abstract

One of the most abundant proteins expressed in the brain, 14-3-3 comprises about 1% of the brain's total soluble proteins. The 14-3-3 isoforms bind to specific phosphoserine- and phosphothreonine-containing motifs found on a variety of signaling proteins (kinases and transcription factors, among others) to regulate a wide array of cellular processes including cell cycling, apoptosis, and autophagy. Previously, we described the expression of different 14-3-3 isoforms in the rat frontal cortex and reported their downregulation in a rodent model of neurodegeneration. To further investigate possible roles of 14-3-3 proteins in neurodegeneration, the present study examined different 14-3-3 isoforms in the frontal cortex of postmortem Alzheimer's disease (AD) patients and control subjects. Among the different 14-3-3 isoforms in the human frontal cortex, the relative abundance of expression is in the following order: 14-3-3-eta > tau > sigma > gamma > epsilon > zeta/delta > beta/alpha. These relative abundance levels of different 14-3-3 isoforms in human frontal cortex closely resemble those in rat frontal cortex, suggesting a conserved expression pattern of different 14-3-3 isoforms in mammalian species. In the AD samples, there was a significant decrease in total 14-3-3 levels and the 14-3-3-eta and 14-3-3-gamma isoforms, while no significant difference in the expression level of other 14-3-3 isoforms between AD and control brains was detected. Together, these results demonstrate an abundance of several 14-3-3 isoforms in the frontal cortex and that a downregulation of total 14-3-3 protein levels and specific 14-3-3 isoforms is associated with neurodegeneration. Given the known function of 14-3-3 proteins as inhibitors of apoptosis, the present results suggest that 14-3-3 proteins may play an important role in neurodegeneration and deserve further investigations into AD and other neurodegenerative disorders.

Entities:  

Keywords:  14-3-3 proteins; Alzheimer’s disease; Apoptosis; Frontal cortex; Neurodegeneration

Mesh:

Substances:

Year:  2019        PMID: 31487003     DOI: 10.1007/s12035-019-01754-y

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  50 in total

1.  Specification of 14-3-3 proteins in Lewy bodies.

Authors:  Daniela Berg; Olaf Riess; Antje Bornemann
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422

2.  Proteomic analysis of hypoxia/ischemia-induced alteration of cortical development and dopamine neurotransmission in neonatal rat.

Authors:  Xiaoming Hu; Harriett C Rea; John E Wiktorowicz; J Regino Perez-Polo
Journal:  J Proteome Res       Date:  2006-09       Impact factor: 4.466

3.  Increased levels of 14-3-3 gamma and epsilon proteins in brain of patients with Alzheimer's disease and Down syndrome.

Authors:  M Fountoulakis; N Cairns; G Lubec
Journal:  J Neural Transm Suppl       Date:  1999

4.  14-3-3 binds to and mediates phosphorylation of microtubule-associated tau protein by Ser9-phosphorylated glycogen synthase kinase 3beta in the brain.

Authors:  Zongfei Yuan; Alka Agarwal-Mawal; Hemant K Paudel
Journal:  J Biol Chem       Date:  2004-04-08       Impact factor: 5.157

5.  Interaction of 14-3-3ζ with microtubule-associated protein tau within Alzheimer's disease neurofibrillary tangles.

Authors:  Hamid Y Qureshi; Tong Li; Ryen MacDonald; Chul Min Cho; Nicole Leclerc; Hemant K Paudel
Journal:  Biochemistry       Date:  2013-09-04       Impact factor: 3.162

6.  Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation.

Authors:  Jui-Sheng Wu; Wai-Mui Cheung; Yau-Sheng Tsai; Yi-Tong Chen; Wen-Hsuan Fong; Hsin-Da Tsai; Yu-Chang Chen; Jun-Yang Liou; Song-Kun Shyue; Jin-Jer Chen; Y Eugene Chen; Nobuyo Maeda; Kenneth K Wu; Teng-Nan Lin
Journal:  Circulation       Date:  2009-02-16       Impact factor: 29.690

7.  The chaperone-like protein 14-3-3η interacts with human α-synuclein aggregation intermediates rerouting the amyloidogenic pathway and reducing α-synuclein cellular toxicity.

Authors:  Nicoletta Plotegher; Dhruv Kumar; Isabella Tessari; Marco Brucale; Francesca Munari; Laura Tosatto; Elisa Belluzzi; Elisa Greggio; Marco Bisaglia; Stefano Capaldi; Daniel Aioanei; Stefano Mammi; Hugo L Monaco; Bruno Samo; Luigi Bubacco
Journal:  Hum Mol Genet       Date:  2014-06-03       Impact factor: 6.150

8.  Three-way interaction between 14-3-3 proteins, the N-terminal region of tyrosine hydroxylase, and negatively charged membranes.

Authors:  Øyvind Halskau; Ming Ying; Anne Baumann; Rune Kleppe; David Rodriguez-Larrea; Bjørg Almås; Jan Haavik; Aurora Martinez
Journal:  J Biol Chem       Date:  2009-09-28       Impact factor: 5.157

9.  Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease.

Authors:  T A Yacoubian; S R Slone; A J Harrington; S Hamamichi; J M Schieltz; K A Caldwell; G A Caldwell; D G Standaert
Journal:  Cell Death Dis       Date:  2010       Impact factor: 8.469

Review 10.  Neuroprotective function of 14-3-3 proteins in neurodegeneration.

Authors:  Tadayuki Shimada; Alyson E Fournier; Kanato Yamagata
Journal:  Biomed Res Int       Date:  2013-12-02       Impact factor: 3.411

View more
  11 in total

1.  Restoration of the reduced CLSP activity alleviates memory impairment in Alzheimer disease.

Authors:  Yuichi Hashimoto; Shinya Kusakari; Mikiro Nawa; Koichi Okamoto; Yuka Toyama; Masaaki Matsuoka
Journal:  Transl Psychiatry       Date:  2021-01-13       Impact factor: 6.222

Review 2.  Traumatic MicroRNAs: Deconvolving the Signal After Severe Traumatic Brain Injury.

Authors:  Martin Cente; Katarina Matyasova; Nikoleta Csicsatkova; Adela Tomikova; Sara Porubska; Yun Niu; Marek Majdan; Peter Filipcik; Igor Jurisica
Journal:  Cell Mol Neurobiol       Date:  2022-07-19       Impact factor: 4.231

3.  Binding of the Human 14-3-3 Isoforms to Distinct Sites in the Leucine-Rich Repeat Kinase 2.

Authors:  Jascha T Manschwetus; Maximilian Wallbott; Alexandra Fachinger; Claudia Obergruber; Sabine Pautz; Daniela Bertinetti; Sven H Schmidt; Friedrich W Herberg
Journal:  Front Neurosci       Date:  2020-04-07       Impact factor: 4.677

4.  Inhibition of 14-3-3 Proteins Alters Neural Oscillations in Mice.

Authors:  Zachary B Jones; Jiajing Zhang; Yuying Wu; Yi Zhou
Journal:  Front Neural Circuits       Date:  2021-03-12       Impact factor: 3.492

5.  Loganin substantially ameliorates molecular deficits, pathologies and cognitive impairment in a mouse model of Alzheimer's disease.

Authors:  Lulin Nie; Kaiwu He; Fengzhu Xie; Shifeng Xiao; Shupeng Li; Jia Xu; Kaiqin Zhang; Chen Yang; Li Zhou; Jianjun Liu; Liangyu Zou; Xifei Yang
Journal:  Aging (Albany NY)       Date:  2021-10-23       Impact factor: 5.682

6.  The Transglutaminase-2 Interactome in the APP23 Mouse Model of Alzheimer's Disease.

Authors:  Micha M M Wilhelmus; Elisa Tonoli; Clare Coveney; David J Boocock; Cornelis A M Jongenelen; John J P Brevé; Elisabetta A M Verderio; Benjamin Drukarch
Journal:  Cells       Date:  2022-01-24       Impact factor: 6.600

7.  NACHO and 14-3-3 promote expression of distinct subunit stoichiometries of the α4β2 acetylcholine receptor.

Authors:  Simone Mazzaferro; Sara T Whiteman; Constanza Alcaino; Arthur Beyder; Steven M Sine
Journal:  Cell Mol Life Sci       Date:  2020-07-16       Impact factor: 9.261

Review 8.  Emerging roles of 14-3-3γ in the brain disorder.

Authors:  Eunsil Cho; Jae-Yong Park
Journal:  BMB Rep       Date:  2020-11       Impact factor: 4.778

9.  Probing the 14-3-3 Isoform-Specificity Profile of Protein-Protein Interactions Stabilized by Fusicoccin A.

Authors:  Ananya Sengupta; Josue Liriano; Ewa A Bienkiewicz; Brian G Miller; James H Frederich
Journal:  ACS Omega       Date:  2020-09-24

10.  Co-Expression Network Analysis of Micro-RNAs and Proteins in the Alzheimer's Brain: A Systematic Review of Studies in the Last 10 Years.

Authors:  Rachel Tasker; Joseph Rowlands; Zubair Ahmed; Valentina Di Pietro
Journal:  Cells       Date:  2021-12-09       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.